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Introduction 
Gestational trophoblastic diseases (GTD), representing a range of 
proliferative disorders that originate from the placenta, fall into two main types, 
the premalignant conditions complete (CHM) and partial hydatidiform mole 
(PHM) and the gestational trophoblastic neoplasms (GTN), invasive mole, 
choriocarcinoma, placental-site trophoblastic tumour (PSTT) and epithelioid 
trophoblastic tumour (ETT).  
 
While CHM and PHM are identified on the basis of histopathological findings 
(Sebire 2010), tissue from IM is rarely seen as most are treated successfully 
with chemotherapy following early detection by human chorionic 
gonadotrophin (hCG) monitoring subsequent to a molar pregnancy.  Most 
other GTN are diagnosed clinically with primary or metastatic disease 
following an unrecognised molar pregnancy or non-molar pregnancy and 
diagnosis confirmed on the basis of histopathological features (Sebire and 
Lindsay 2010). 
 
Choriocarcinoma, occurs in approximately 1 in 30,00 to 40,000 pregnancies in 
Europe and North America (Smith 2003). Histopathologically, these tumours 
show differentiation towards villous trophoblast and are characterised by 
proliferation of mononuclear cytotrophoblast-like and multinucleated 
syncytiotrophoblast-like cells surrounding necrotic and haemorrhagic tissue 
(Sebire and Lindsay 2010).  
 
PSTT, first described as a separate entity in 1976 (Kurman et al 1976) and 
recognised as a malignant trophoblastic tumour in 1981 (Scully and Young 
1981) are biologically unique from choriocarcinoma due to their relatively slow 
growth rate, lower human chorionic gonadotropin (hCG) serum levels, later 
onset of metastatic potential and greater resistance to chemotherapy. These 
tumours are characterized by differentiation towards implantation site-
trophoblast and appear as a monomorphic population of large polyhedral cells 
with irregular hyperchromatic nuclei (Sebire and Lindsay 2010).  
 
More recently a third tumour, epithelioid trophoblastic tumour (ETT), has been 
established as a rare variant of GTN with its own distinct morphology and 
immunohistochemical features (Shih and Kurman 1998). ETT is characterised 
by transformation of the chorionic-type intermediate trophoblastic cells. 
Clinically these tumours closely exhibit similar behaviour to PSTT. 
Occasionally mixed tumours, having elements of both choriocarcinoma and 
PSTT or both PSTT and ETT have been described (Shih and Kurman 2001).  
 
Choriocarcinoma may follow any type of pregnancy but most commonly 
occurs after an abnormal pregnancy, approximately 40 - 50% following a 
pregnancy with a HM (Bagshawe et al 1976; Lurain et al 1982). In contrast, 
reports suggest that PSTT and ETT are more likely to follow a normal term 
pregnancy (Shih and Kurman 1998; Chang et al 1999; Baergen et al 2006; 
Palmer et al 2008; Schmid et al 2009) with a strong bias towards presenting 
after a female pregnancy (Hui et al 2000; Hui et al 2007).  Molecular 
genotyping of twenty PSTT found the presence of one or more X 
chromosomes together with the absence of a Y chromosome in all cases 
suggesting that the presence of paternally derived X chromosome may be 
required for the pathogenesis of PSTT.  A subsequent study of the Y 
chromosomal complement in GTN did identify a single case of PSTT (7%) 
and three ETT (18%) with Y chromosomes but confirmed that the majority of 
both PSTT and ETT were female (Yap et al 2010). 
 
The antecedent pregnancies were not reported in these studies and one 
explanation for the very high numbers of female pregnancies might be that, 
like choriocarcinoma, the causative pregnancy in a large proportion of PSTT 
and ETT might be a CHM. Since approximately 90% of CHM are female 
(Fisher et al 1989; Cheung et al 1994) then a bias towards female tumours 
would be expected. Although few PSTT and ETT are reported to occur 
following a HM, it has been clearly shown that in choriocarcinoma at least, the 
causative pregnancy may not be the antecedent pregnancy  (Fisher et al, 
1995, Shahib et al 2001, Fisher et al 2007). 
The aim of this study was to investigate a large series of PSTTs and ETTs, 
treated at a national trophoblastic disease centre, to further elucidate the 
relationship between the nature and sex of both the antecedent and causative 
pregnancies and the development of these rare tumours.  
 
Materials and methods 
Patient Cohort 
All PSTT and ETT cases referred to the Charing Cross Hospital Trophoblastic 
Tumour Screening and Treatment Centre were identified from the electronic 
data bases of the unit. Between January 1976 and January 2016 ninety two 
cases with a confirmed diagnosis of PSTT, ETT or mixed PSTT/ETT were 
referred to Charing Cross Hospital, the first two cases being unusual 
trophoblastic tumours that were diagnosed as PSTT on pathological review in 
1981. The site and histopathological diagnosis of the tumour, together with 
available obstetric history including the nature and sex of the antecedent 
pregnancy and time interval until diagnosis was recorded  for each case. 
 
Histopathology  
The histopathology of all cases was reviewed at the trophoblastic disease 
unit, by specialist histopathologists with expertise in GTD, using criteria based 
on the World Health Organisation classification of tumours of the female 
reproductive organs (Hui et al 2014). Confirmatory immunohistochemical 
staining with markers such as placental alkaline phosphatase, human 
placental lactogen and P63 were carried out as appropriate.     
 
Molecular Genotyping 
DNA extraction 
Tumour and adjacent maternal tissue were dissected independently from 3-5 
unstained 5µ sections of formalin fixed paraffin embedded tissue with 
reference to a consecutive haematoxylin and eosin stained section. Following 
deparaffinisation of the tissue, DNA was prepared by digesting the tissue in a 
buffer comprising 50mM Tris pH 8.5; 1mM EDTA pH 8.0; 0.5% Tween 20 and 
200µg/ml proteinase K at 56ºC for 3 hours, the volume determined by the 
amount of tissue available. Following heat inactivation of the proteinase K at 
95°C for 8 min, the solution containing DNA was stored at -20oC until use. In 
nine cases DNA was prepared from children of antecedent pregnancies. In 
these cases saliva samples were collected in an Oragene DNA collection kit 
(DNA Genotek, Ottawa, Canada) and DNA prepared according to 
manufacturer’s instructions. In 3 cases DNA was prepared from a 200 µl 
blood sample from the patient’s partner using a QIAamp DNA mini kit 
(QIagen, UK) as per the manufacturer’s protocol.  
 
Fluorescent microsatellite genotyping 
1 µl DNA from tumour and maternal tissue (or 20ngs DNA from saliva) was 
amplified with primers for 15 short tandem repeat (STR) loci on 13 
chromosomes, together with the amelogenin locus, using an AmpFlSTR 
Identifiler Plus kit (Applied Biosystems, Warrington, UK). PCR products were 
resolved by capillary electrophoresis using an ABI 3100 Genetic Analyser and 
genotypes determined using GeneMapper version 4.0 software (Applied 
Biosystems, Warrington, UK). The genotype of the tumour tissue was 
compared with that of the maternal tissue to determine the gestational origin 
of disease. In cases where the parental origin of the X chromosome was 
identified,  1 µl of DNA from the tumour and maternal tissue, together with 20 
ngs of  DNA from her partner, were amplified with primers for two polymorphic 
dinucleotide repeats DXS451 and DXS984. 
 
Statistical analysis  
Frequencies of female genotypes between groups were examined using 
comparison of proportions test (modified chi squared test) using StatsDirect 
(UK). P<0.05 was considered significant. 
 
Ethical approval  
The project was approved (project no, R14032) by the Tissue Management 
Committee of the Imperial College Healthcare NHS Trust Research Tissue 
Bank (project no. R14032), which is approved by NRES to provide deemed 
ethics for projects accessing material and data stored within the Research 
Tissue Bank. 
 
Results 
Patient characteristics 
Ninety-two patients were identified from the electronic databases at Charing 
Cross Hospital with a diagnosis of PSTT, ETT or a mixed tumour containing 
elements of PSTT and or ETT. The majority of tumours were morphologically 
PSTT (66%), approximately 25% ETT or mixed PSTT/ETT and a smaller 
number of mixed tumours containing elements of choriocarcinoma (Figure 1; 
Table 1). 
 
 
Figure 1. Photomicrographs of haematoxylin and eosin stained placental 
site trophoblastic, epithelioid and mixed trophoblastic tumours showing 
representative morphological features.  A. Typical PSTT exhibiting sheets 
of monomorphic interstitial trophoblast cells with eosinophilic cytoplasm and 
minimal atypiaB. ETT demonstrating extravillous trophoblast with areas of 
hyalinisation. A mixed PSTT (left panel) and ETT (right panel). D a mixed 
PSTT (left panel) with choriocarcinoma (right panel, demonstrating more 
marked atypia and focal syncytiotrophoblastic differentiation). (original 
magnifications x100).   
 
Pathology Cases Age at diagnosis 
(years)  
Time since 
antecedent pregnancy 
(years) 
  
Mean Range Mean Range 
PSTT 61  (66%) 33.3 20 - 54 2.68 0.1 - 21.5 
ETT 11  (12%) 36.5 15 - 49 3.27 0.9 - 13.3 
Mixed PSTT/ETT 11  (12%) 37.4 28 - 45 6.34 1.0 - 18.9 
Mixed PSTT/CC 8   (9%) 37.2 23 - 59 4.98 0.9 - 18.5 
Mixed ETT/CC 1   (1%) 47 - 3.15 - 
Total    92 34.7 15 - 59 3.40 0.1 - 21.5 
 
Table 1. Characteristics of patients included in the study 
 
 
 
Antecedent Pregnancy 
The antecedent pregnancy as recorded in patient notes showed that this was 
a full term normal delivery in over half (64%) of cases.  In 19 (21%) cases the 
tumour was preceded by a molar pregnancy, the majority of these being 
morphologically CHM. In the remaining 15% of cases the antecedent 
pregnancy was miscarriage (6.5%), termination of pregnancy (7.5%) or still 
birth (1%) (Table 2). The sex of the antecedent pregnancy was not recorded 
in eleven cases. In the remaining singleton pregnancies a significantly greater 
proportion were reported as female, 35 of 45 (78%) than male, 10 of 45 (22%) 
(p < 0.0001; 95% confidence interval 0.629-0.889). In one of two cases in 
which the antecedent pregnancy was twins, both infants were female and the 
other one male and one female.  
 
    
                     Live birth           HM Other 
 Cases Female Male NK twins CHM Other Miscarriage TOP Still 
Birth 
PSTT 61 22 7 9 M/F 8 HM -2 
PHM -1 
5 5 * 1 
ETT 11 4  1  5    1  
Mixed PSTT/ETT 11 6 2  F/F 1   1   
Mixed PSTT/CC 8 4 1 1  1    1  
Mixed ETT/CC 1     1      
Total 92 36 10 11 2 16 3 6 7 1 
 
Table 2. Antecedent pregnancies reported for cases in the study. M, 
male; F, Female; NK, Not known; HM hydatidiform mole; CHM, complete  
hydatidiform mole; TOP, termination of pregnancy; PHM, partial hydatidiform 
mole; *Includes one case of late termination for spina bifida. 
 
Causative pregnancy 
In 15 cases H and E stained slides, without further pathological material, were 
sent to the unit for review. In a further eight cases, histological blocks had 
been returned to the referring hospital following pathological review and were 
not available for analysis. DNA was prepared and genotyping performed for 
all 69 cases in which tumour tissue was available. In some cases larger 
alleles at some loci included in the AmpflSTR kit failed to amplify on 
genotyping due to DNA degradation of archival material. Only cases in which 
three or more non-maternal (paternal) alleles were identified in the tumour, 
and hence a gestational origin confirmed, were included in the study. 
Contamination of tumour DNA with DNA from the patient was present to some 
degree in most of the tumours due to difficulties in microdissection of tumours 
which infiltrate the normal maternal myometrium and infiltration of the tumour 
tissue by maternal lymphocytes. Eight cases, including six where the tumour 
tissue was over 20 years old, and four cases where insufficient unique 
paternal alleles were identified to confirm a diagnosis due to maternal 
contamination, were excluded from the study. Of the 57 tumours analysed, 48 
were from the primary tumour, in three cases lung metastases, two cases 
pelvic metastases and one case the ovary. Forty-two tumours were found to 
have arisen in non-molar pregnancies, having both a maternal and paternal 
contribution to the tumour genome (Figure 2;) and 15 in molar pregnancies 
(Figure 3) (Table 3). 
 
 
 
 
 
 Figure 2. Partial genotypes of maternal and tumour tissue in a case of  
PSTT/ETT following a normal term birth. Genotyping of the tumour for STR 
loci D13S317, D16S569 and D2S1338 (and others not shown) show a single 
non-maternal allele (solid peak). Both maternal alleles (open peaks) are 
present in the tumour DNA, the lower peak representing maternal 
contamination while the higher peak represents a maternal contribution to the 
tumour genome, and a small proportion of maternal contamination. DNA at 
the AMEL locus is from the X chromosome only. 
 Figure 3. Partial genotypes of maternal and tumour tissue in a case of  
PSTT/ETT following an antecedent molar pregnancy. Genotyping of the 
tumour for STR loci D3S1358, D21S11 and D7S220 (and others not shown) 
show a single non-maternal allele (solid peak). DNA at the AMEL locus is 
from the X chromosome only. 
 
  Non-molar Molar 
Pathology Cases Female Male Female Male 
PSTT 33 22 2 8 1 PHM 
ETT 8 5 - 2 1 BiCHM 
Mixed PSTT/ETT 9 7 1 1 - 
Mixed PSTT/CC 6 4 1 - 1 
Mixed ETT/CC 1 - - 1 - 
Total 57 38 4 12 3 
 
Table 3: Causative pregnancy identified by genotyping of maternal and 
tumour tissue. PHM, partial hydatidiform mole; BiCHM diploid biparental 
complete hydatidiform mole. 
 In tumours where the causative pregnancy was non-molar, a significantly 
greater number were female than male (p <0.0001; 95% confidence interval 
0.219 - 0.569) only 4 of 42 cases (9.5%) having a Y chromosomal allele 
present (Figure 4). 
 
Figure 4. Partial genotypes of maternal and tumour tissue in a case of  
PSTT/CC following a male term birth. Genotyping of the tumour for STR 
loci D3S1358, THO and D5S818 (and others not shown) show a single non-
maternal allele (solid peak). Both maternal alleles (open peaks) are present in 
the tumour DNA, the lower peak representing maternal contamination while 
the higher peak represents a maternal contribution to the tumour genome, 
and a small proportion of maternal contamination. DNA at the AMEL locus is 
from both the X and Y chromosome. 
Three of the fifteen tumours following molar pregnancies were shown to have 
a Y chromosome. One of these was a tumour in which the causative 
pregnancy was a PHM and the other a tumour that had originated in a 
dispermic CHM. In a third case a patient with familial recurrent hydatidiform 
mole, a condition in which women have CHM that are diploid and biparental 
rather than androgenetic developed a PSTT following a CHM.   Although the 
pregnancy was diploid and biparental, due to the patient’s condition, this 
tumour was considered to have arisen in a diploid biparental CHM with a Y 
chromosome. In the 12 post-mole tumours of female origin, all autosomal 
markers were homozygous inconsistent with a monospermic origin. 
In twelve of the 14 cases where a CHM was the causative pregnancy, the 
antecedent pregnancy was reported as a CHM (Table 4). In five cases where 
tissue was available from the antecedent molar pregnancy, genotyping 
confirmed that the antecedent pregnancy was the causative pregnancy. In 
one case the molar pregnancy was not classified and sections unavailable for 
review while one case was reported as a miscarriage.  The single case where 
a PHM was the causative pregnancy, the antecedent pregnancy was also 
reported as a PHM. 
The antecedent pregnancies in all four cases in which a non-molar male 
conception was the causative pregnancy were full term normal deliveries of 
male infants. In the 38 cases in whichthe causative pregnancy was non-molar 
female, the sex of the antecedent pregnancy was unknown in 13, a 
miscarriage in two and termination of pregnancy in five. In the 28 cases of 
causative pregnancy reported to follow normal term delivery, 25 cases, 
including one case of female twins, were reported as female. Interestingly the 
causative pregnancy in three cases in which the antecedent pregnancy was 
reported as male had no Y chromosomal material (Table 4).  
Causative Pregnancy 
                                  Cases 
Antecedent Pregnancy 
                                  Cases 
CHM Female 12 CHM 10 
  HM 1  
  SA 1 
CHM Male 3 CHM 2 
  PHM 1 
Non-molar male 4 FTND male 4 
Non-molar female 38 FTND female 24 
  FTND NK 3 
  FTND female twins 1 
  FTND male 3 
  SA 2 
  TOP 5 
 
Table 4: Antecedent pregnancies in cases where causative pregnancy was 
identified by genotyping. CHM, complete hydatidiform mole; HM, hydatidiform 
mole; PHM, partial hydatidiform mole; SA, spontaneous abortion; FTND, full 
term normal delivery; NK, Not known, TOP, termination of pregnancy. 
Genotyping of the child from the antecedent pregnancy was not performed in 
most cases. However, in nine cases genotyping of the child was performed to 
confirm the time interval between the pregnancy and diagnosis, an important 
risk factor for PSTT and ETT. In eight of these cases the genotype of the 
antecedent pregnancy was consistent with that of the tumour. In one case of 
PSTT/ETT both the antecedent pregnancy and causative pregnancy were 
non-molar female conceptions. However, the genotype of the causative 
pregnancy was different to that of the antecedent pregnancy (Figure 5). 
Subsequent genotyping of other pregnancies in the patient showed that the 
tumour had originated in the pregnancy with her elder sister (Figure 5).  
 
Figure 5. Partial genotypes of tumour tissue in a case of PSTT/ETT 
following a female term birth. Both the tumour and antecedent pregnancy 
are female. However, genotyping of the tumour for STR loci D8S1179, 
D21S11 and D2S1338 (and others not shown) identified alleles in the tumour 
which were not present in DNA from the child of the antecedent pregnancy 
(solid peaks). Genotyping of the child from the previous pregnancy identified a 
genotype consistent with that in the tumour. 
In three cases where genotyping of the child of the antecedent pregnancy 
confirmed that the tumour had arisen in the antecedent male pregnancy, 
genotyping of two STR polymorphisms on the X chromosome in maternal, 
tumour and paternal DNA confirmed that the tumour had only a single X 
chromosome of maternal origin (Table 5). 
 
   
  Short Tandem Repeat 
Case  DXS451 DXS984 
 
Patient 186 166 
49 PST/CC 186 166 
 
Partner 174 182 
 
   
 
Patient 174 - 193 166 - 176 
62 PSTT 193 166 
 
Partner 178 166 
 
   
 
Patient 186 - 190 166 - 170 
85 PSTT/ETT 186 166 
 
Partner 186 178 
 
Table 5:  Allele sizes (base pairs) identified following amplification with primes 
for dinucleotide short tandem repeats DXS451 and DXS984 in 3 tumours with 
a Y chromosome.  
 
Discussion 
PSTT, a rare form of trophoblastic tumour originating in intermediate 
trophoblast (Kurman et al 1976), represents about 0.2% of patients with 
gestational trophoblastic disease in the UK (Schmid et al 2009). Since the 
recognition of ETT a second tumour arising from intermediate trophoblast, in 
1998 (Shih and Kurman 1998), the majority of these tumours, 63% are still 
classified as PSTT. Approximately 17% have been classified as ETT while the 
remaining 20% represent mixed tumours with populations of cells resembling 
ETT and PSTT. 
While PSTT and ETT can follow any type of pregnancy, the antecedent 
pregnancy is most likely to be a normal term pregnancy (Shih and Kurman 
1998; Chang et al 1999; Baergen et al 2006; Palmer et al 2008; Schmid et al 
2009). However, when the sex of these pregnancies has been recorded the 
approximate equal numbers of male and female pregnancies expected has 
not been observed, a review of the literature showing 21 of 23 antecedent 
pregnancies in a series of PSTT were female. This prompted the suggestion 
that the pathogenesis of PSTT might require a paternally derived X 
chromosome (Hui et al 2000). Subsequent molecular genotyping to identify 
the causative pregnancy in series of PSTT found none of the twenty cases 
examined to have a Y chromosome (Hui et al 2007). A further study of the Y 
chromosomal complement in GTN did identify a single case of PSTT (7%) 
and three ETT (18%) with Y chromosomes but confirmed that the majority of 
both PSTT and ETT were female (Yap et al 2010). Although the tumours 
investigated were confirmed to be gestational in the study by Hui et al (2000) 
the nature of the causative pregnancy was not determined in either study 
leading Yap et al (2010) to hypothesise that the absence of the Y 
chromosomal component could to be due to the majority of GTN originating in 
CHM, in which most of the cases are genetically XX (Fisher et al 1989), rather 
than the recognised antecedent pregnancy. While it has been reported that 
the causative pregnancy in choriocarcinomas is not always the antecedent 
pregnancy (Fisher 1995; Shahib et al 2001; Fisher et al 2007) and we have 
observed post-mole choriocarcinoma in women without a history of a 
recognised molar pregnancy, this has not yet been demonstrated for other 
types of trophoblastic tumours. 
In the present study investigation of a large series of PSTT and ETT has 
confirmed that most antecedent pregnancies, based on patient history, and  
most causative pregnancies, determined by genetic analysis, are female. Of 
the 92 cases included in the study the majority, 61, were PSTT.  While PSTT 
and ETT are thought to arise from different subpopulations of intermediate 
trophoblast (Shih and Kurman 2001), the number of ETT was small, the 
behavior of ETT closely resembles that of PSTT and some tumours had 
elements of both PSTT and ETT, the tumours were considered as one group 
for analysis.  
The nature of the antecedent pregnancy for tumours in this study was similar 
to that reported in earlier studies with 64% of tumours following term 
pregnancies, 21% following molar pregnancies and 15% following other 
pregnancy losses.  Most antecedent molar pregnancies were reported as 
CHM with two cases of undefined origin and one PHM, confirming that, like 
other types of GTN the major risk factor for a post-mole tumour is a 
pregnancy with a CHM.  
Genotyping was performed in a subset of these patients, for whom 
pathological material was available. While the AmpFISTR Identifiler PCR 
assay failed to amplify some of the larger products for autosomal loci, due to 
degradation of the FFPE material, the polymorphic products generated for the 
X and Y loci of 106 and 110 base pairs respectively, amplified consistently. 
However, only the 57 cases where three or more informative loci confirmed 
the presence of non-maternal alleles in the tumour, and therefore a 
gestational origin, were included in the study. Genotyping of these cases 
demonstrated that the causative pregnancy in most PSTT and ETT is not, as 
previously hypothesized (Yap et al 2010) a CHM since 74% of tumours were 
shown to originate in non-molar pregnancies with both a maternal and a non-
maternal contribution to the tumour genotype. Of the 15 tumours that did 
originate in molar pregnancies, the causative molar pregnancy was a PHM in 
one while the remaining 14 were CHM. Of these one was unusual in that it 
had originated in a diploid biparental CHM in a patient with familial recurrent 
hydatidiform mole, a genetic disorder in which women have an inherited 
predisposition to molar pregnancies (Fisher et al 2004; Nguyen and Slim 
2014). While most CHM are monospermic, approximately 20% are dispermic 
(Fisher et al 1989). The relevant malignant potential of the two types of CHM 
remains controversial (Bynum et al 2016). The fact that only a single CHM in 
the study was dispermic, having a heterozygous genotype while twelve were 
homozygous for all alleles analysed and therefore monospermic, does not 
support the hypothesis that dispermic CHM have a more malignant potential 
than monospermic CHM.  
The present study did demonstrate that both antecedent and causative 
pregnancies that originated in non-molar pregnancies were mostly, but not 
exclusively, female. In tumours following singleton non-molar pregnancies the 
sex of the antecedent pregnancy was reported to be male in 10 of 46 (22%) 
and where the causative pregnancy was identified 4 out of 42 (10%) 
apparently failing to support the hypothesis that a paternally derived X is 
essential for the development of PSTT.  In order to confirm that where the 
causative pregnancy was male these tumours did not also harbour a second 
male-derived X chromosome, genotyping of two polymorphisms on the X 
chromosome was performed in three cases where paternal DNA was 
available. No unique paternal alleles were found in any of the three tumours, 
only a single maternal allele being present for all informative markers. A 
paternally derived X does not therefore appear to be a requirement for tumour 
development. While there were fewer cases of ETT or mixed tumours than 
PSTT, the proportion of male to female tumours appeared similar in the 
different groups. Histopathological review revealed no differences between 
male and female tumours of the same morphological type.  
Amongst causative pregnancies fewer male pregnancies were observed than 
in the antecedent group, only 4 of 42 (10%) non-molar pregnancies being 
male. This may reflect the fact that “non-molar pregnancies” comprise slightly 
cases in the two groups. The antecedent pregnancy group includes only term 
pregnancies for which the sex is known whereas in the causative pregnancy 
group non-molar pregnancies include term births and other reproductive loss. 
For three cases of PSTT with a male antecedent pregnancy, the tumour was 
female on genotyping, suggesting some tumours in the study had lost the Y 
chromosome during tumour progression, a feature of a number of different 
malignancies (Hunter et al 1993; Brunelli et al; 2003; Bianchi et al 2009). 
While it is not possible to confirm loss of the Y chromosome during 
progression in these cases without knowing the genotype of the child for the 
antecedent pregnancy, it is interesting that the mean time interval between 
the antecedent pregnancy and diagnosis for the three tumours that have 
apparently lost their Y chromosome is 7.16 years (range 3.90 - 8.85 years) 
compared to the mean interval between the antecedent pregnancy and 
diagnosis in the four cases where both antecedent and causative pregnancy 
were male, 2.98 years (range 1.38 - 5.78 years).  
The genotype of the antecedent pregnancy is not available in most cases. 
However, since the demonstration that the time interval between the 
antecedent pregnancy and diagnosis of PSTT is the single most important 
prognostic factor for women with these tumours (Schmid et al 2009), 
genotyping of the child of the antecedent pregnancy has been performed in a 
small number of cases. In 13 of 14 cases, 5 CHM and eight non-molar 
pregnancies, the genotype of the tumour was consistent with the antecedent 
pregnancy. In only one case of a mixed PSTT/ETT was the antecedent 
pregnancy not the causative pregnancy. This provides confirmation that in 
PSTT and ETT, like choriocarcinoma, the antecedent pregnancy may not be 
the causative pregnancy. However, this is a rare event and most PSTT and 
ETT are therefore unlikely to have arisen in unrecognised molar pregnancies.  
Although only 25% of PSTT and ETT arise in molar pregnancies, given that 
only one in 600 pregnancies in the UK are HM, (Savage et al 2013), this 
represents a considerable malignant potential for molar pregnancies. Since 
the abnormal pathology of HM reflects the fact that most have two copies of 
the paternal genome and therefore exhibit aberrant expression of imprinted 
genes it is likely that this also drives the development of post-mole tumours. 
We hypothesise that tumours originating in non-molar pregnancies may also 
arise as a result of aberrant expression of imprinted genes in the placental 
tissue and, given the high propensity for tumours to follow female 
pregnancies, that the defect might also involve over expression of genes on 
the X chromosome one of which is normally inactivated in female pregnancies 
(Morey and Avner 2010). It may be the presence of two active X 
chromosomes that is important for tumour development rather than the 
presence of a paternal X chromosome per se.  
Since a greater proportion of choriocarcinoma do follow CHM, they are 
expected to be predominately female. in an earlier report in which the sex of a 
variety of trophoblastic tumours was examined, only 5% of choriocarcinoma 
were male. This would suggest that in the order of 90% of choriocarcinoma 
follow CHM, a figure much higher than any cited in the literature. To address 
this we analysed the sex of a series of tumours that were pathologically 
choriocarcinoma and for which genotyping was performed to determine 
whether they were gestational or non-gestational tumours. Among 13 tumours 
that were confirmed to be gestational and to have originated in non-molar 
pregnancies, only three were male, suggesting there may also be a bias 
towards an origin in female pregnancies in choriocarcinoma following non-
molar pregnancies.  
 
The mechanism by which the small number of tumours deriving in male 
pregnancies arise remains obscure but the presence of a Y chromosome may 
be a favourable prognostic indicator in a tumour following a non molar 
pregnancy. All nineteen patients with a post-mole tumour remain alive and 
well, as do 10 women with tumours arising in tumours with an antecedent 
male pregnancy while only 28 of 37 patients with an antecedent female 
pregnancy remain alive and well. 
 
In conclusion this study has shown that PSTT and ETT can develop in male 
pregnancies and that a male derived X chromosome is not required for 
tumour development. While the study has confirmed that the majority of 
PSTT, ETT and mixed tumours originate in female pregnancies this is 
because most develop in non-molar pregnancies that are female rather than 
because they arise in unrecognised pregnancies with CHM. We have shown 
that PSTT/ETT may arise in a pregnancy other than the antecedent 
pregnancy but that this is a rare event and the antecedent pregnancy is 
usually the causative pregnancy.  We provide preliminary data to suggest 
there is also a predominance of female tumours amongst post-term 
choriocarcinoma and that the mechanisms leading to malignant development 
may therefore be similar in different types of GTN.  While GTN following non-
molar pregnancies is rare, there is a 13.6% per cent chance of GTN following 
a CHM (Savage et al 2013) and identifying women at risk is important in the 
clinical management of these women. Epigenetic investigation of tumours 
arising in non-molar pregnancies may provide insights into the underlying 
mechanisms that give rise to GTN and provide useful markers to enable 
earlier identification of those CHM that will progress to GTN. 
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